Odyssey Therapeutics Inc Dossier - Source-backed chat

Odyssey Therapeutics Inc

ODTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $20.42Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $981.4M

Shares Outstanding 48.1M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Odyssey Therapeutics (Nasdaq: ODTX) is a clinical-stage biopharmaceutical company that successfully went public in May 2026, raising $304 million in an upsized IPO and concurrent private placement. The company is uniquely positioned to disrupt the immunology and inflammation (I&I) space by targeting upstream innate immune signaling pathways rather than single downstream cytokines. Its lead asset, OD-001 (an oral RIPK2 scaffolding inhibitor), recently achieved clinical proof-of-concept in a Phase 2a trial for moderate-to-severe ulcerative colitis, demonstrating a 27% clinical remission rate and a 61% clinical response rate over 12 weeks with a clean safety profile. Backed by a robust cash position of $464 million (pro forma as of March 31, 2026) providing a runway into the second half of 2028, Odyssey has the financial flexibility to advance its lead program into Phase 2b and combination trials, while transitioning its second asset, OD-002, into the clinic.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$26.00

Mean target$32.00

High · most bullish analyst$40.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$26.0020%

OD-001 encounters safety signals or fails to show competitive efficacy in larger, randomized Phase 2b trials, or the combination trial with vedolizumab fails to show synergistic benefits. Additionally, regulatory delays push back the CTA filing for OD-002, or early clinical data for OD-002 shows poor bioavailability or off-target toxicities, severely devaluing the platform.

Base CaseCentral scenario

$32.0050%

Matches the consensus mean

OD-001 successfully initiates its Phase 2b monotherapy and Phase 2a combination trials in H2 2026, with topline data in H2 2027 confirming the efficacy and safety profile observed in Phase 2a. OD-002 completes IND-enabling studies and files a CTA in H2 2026, leading to Phase 1 initiation in H1 2027. The company maintains its cash runway into 2028, and the stock trades in line with peer clinical-stage immunology biotechs.

Bull CaseUpside scenario

$40.0030%

OD-001 demonstrates superior efficacy in the upcoming Phase 2b monotherapy and Phase 2a combination trials with vedolizumab, establishing it as a best-in-class oral therapy that breaks the therapeutic ceiling in IBD. Concurrently, OD-002 successfully enters Phase 1/2a clinical trials for lupus with positive initial safety and biomarker data, validating Odyssey's AI/ML-driven drug discovery platform. Rapid clinical progress attracts lucrative big pharma partnerships or makes the company a prime acquisition target.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong clinical proof-of-concept for lead asset OD-001 in ulcerative colitis, showing a 27% remission rate in a difficult-to-treat patient population.
Robust balance sheet with $464 million in cash (pro forma) providing a runway into the second half of 2028, mitigating near-term dilution risk.
Differentiated scientific approach targeting upstream nodes of inflammatory signaling (RIPK2, SLC15A4) to achieve deeper and more durable remission.
Highly experienced leadership team led by serial biotech entrepreneur Gary Glick, Ph.D., with a proven track record of successful drug development and company exits.

Key Investment Risks

Clinical development risk: OD-001 must prove its efficacy and safety in larger, placebo-controlled Phase 2b trials.
Regulatory risk: Delays in CTA filings or IND clearances for preclinical assets like OD-002 could slow down pipeline expansion.
Intense competition in the IBD and immunology space from established biologics and emerging oral small molecules.

Thesis Invalidation Triggers

Failure of OD-001 to meet primary endpoints in the upcoming Phase 2b monotherapy trial.
Unexpected serious adverse events (SAEs) leading to clinical holds on OD-001 or OD-002.
Significant delay or rejection of the CTA filing for OD-002 in the second half of 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.